Skip to main content
Erschienen in: International Urogynecology Journal 7/2012

01.07.2012 | Original Article

The role of serum C-reactive protein in women with lower urinary tract symptoms

verfasst von: Sheng-Mou Hsiao, Ho-Hsiung Lin, Hann-Chorng Kuo

Erschienen in: International Urogynecology Journal | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Some lower urinary tract dysfunction (LUTD) subtypes may be associated with low-grade inflammation. This study aimed to investigate the role of serum C-reactive protein (CRP) levels in women with lower urinary tract symptoms (LUTS).

Methods

A total of 197 consecutive women with non-stress urinary incontinence (non-SUI) LUTS and 18 healthy women without LUTS (normal controls) were enrolled. LUTS include urinary storage, voiding, and post-micturition symptoms. Patients with previous bladder or urethral surgery, active urinary tract infections, or possible neurogenic lesions were excluded. Serum CRP levels were measured before any treatment was given. Patients were stratified to LUTD subgroups based on a 3-day voiding diary, uroflowmetry, and selective videourodynamic studies.

Results

Median CRP levels were significantly higher in women with overactive bladder (OAB) wet (i.e., with urgency incontinence, n = 30, 0.12 mg/dl) than those in women with bladder oversensitivity (n = 68, 0.075 mg/dl, P = 0.008) and the control group (0.055 mg/dl, P = 0.032). Further analysis revealed that body mass index and maximum flow rate were two independent factors that affected CRP levels. The area under the receiver-operating characteristic curve for using CRP to predict OAB wet was 0.55, and the most predictive cutoff point for CRP was 0.15 mg/dl (sensitivity 43.5 %, specificity 72.7 %).

Conclusions

High serum CRP levels were found in women with OAB wet, and they were related to lower maximum urinary flow rates and higher body mass indices in non-SUI LUTD. However, serum CRP is not a suitable biomarker for discriminating between subtypes of non-SUI LUTD.
Literatur
1.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26PubMedCrossRef Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26PubMedCrossRef
2.
Zurück zum Zitat Hung MJ, Ho ES, Shen PS et al (2006) Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. J Urol 176:636–640PubMedCrossRef Hung MJ, Ho ES, Shen PS et al (2006) Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. J Urol 176:636–640PubMedCrossRef
3.
Zurück zum Zitat Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562PubMedCrossRef Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562PubMedCrossRef
4.
Zurück zum Zitat Tyagi P, Barclay D, Zamora R et al (2010) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42:629–635PubMedCrossRef Tyagi P, Barclay D, Zamora R et al (2010) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42:629–635PubMedCrossRef
5.
Zurück zum Zitat Khasriya R, Khan S, Lunawat R et al (2010) The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol 183:1843–1847PubMedCrossRef Khasriya R, Khan S, Lunawat R et al (2010) The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol 183:1843–1847PubMedCrossRef
6.
Zurück zum Zitat Cartwright R, Afshan I, Derpapas A, Vijaya G, Khullar V (2011) Novel biomarkers for overactive bladder. Nat Rev Urol 8:139–145PubMedCrossRef Cartwright R, Afshan I, Derpapas A, Vijaya G, Khullar V (2011) Novel biomarkers for overactive bladder. Nat Rev Urol 8:139–145PubMedCrossRef
7.
Zurück zum Zitat Antunes-Lopes T, Pinto R, Carvalho-Barros S et al (2011) Urinary levels of brain derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur Urol Suppl 10:277–278CrossRef Antunes-Lopes T, Pinto R, Carvalho-Barros S et al (2011) Urinary levels of brain derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur Urol Suppl 10:277–278CrossRef
8.
Zurück zum Zitat Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681–1685PubMedCrossRef Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681–1685PubMedCrossRef
9.
10.
Zurück zum Zitat Chung SD, Liu HT, Lin H, Kuo HC (2011) Elevation of serum C-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 30:417–420PubMedCrossRef Chung SD, Liu HT, Lin H, Kuo HC (2011) Elevation of serum C-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 30:417–420PubMedCrossRef
11.
Zurück zum Zitat Kupelian V, McVary KT, Barry MJ et al (2009) Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology 73:950–957PubMedCrossRef Kupelian V, McVary KT, Barry MJ et al (2009) Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology 73:950–957PubMedCrossRef
12.
Zurück zum Zitat St Sauver JL, Sarma AV, Jacobson DJ et al (2009) Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 169:1281–1290PubMedCrossRef St Sauver JL, Sarma AV, Jacobson DJ et al (2009) Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 169:1281–1290PubMedCrossRef
13.
Zurück zum Zitat Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68:318–323PubMedCrossRef Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68:318–323PubMedCrossRef
14.
Zurück zum Zitat Nixon A, Colman S, Sabounjian L et al (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604–607PubMedCrossRef Nixon A, Colman S, Sabounjian L et al (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604–607PubMedCrossRef
15.
Zurück zum Zitat Chung SD, Liao CH, Chen YC, Kuo HC (2011) Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Neurourol Urodyn 30:1300–1304PubMed Chung SD, Liao CH, Chen YC, Kuo HC (2011) Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Neurourol Urodyn 30:1300–1304PubMed
16.
Zurück zum Zitat Kuo HC (2005) Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology 66:1005–1009PubMedCrossRef Kuo HC (2005) Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology 66:1005–1009PubMedCrossRef
17.
Zurück zum Zitat Kuo YC, Kuo HC (2012) Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversensitivity in women. Int J Clin Pract 66:146–151. doi:10.1111/j.1742-1241.2011.02767.x Kuo YC, Kuo HC (2012) Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversensitivity in women. Int J Clin Pract 66:146–151. doi:10.​1111/​j.​1742-1241.​2011.​02767.​x
18.
Zurück zum Zitat Altman DG (1991) Relation between several variables. In: Altman DG (ed) Practical statistics for medical research. Chapman & Hall, London, pp 325–364 Altman DG (1991) Relation between several variables. In: Altman DG (ed) Practical statistics for medical research. Chapman & Hall, London, pp 325–364
19.
Zurück zum Zitat Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P (2010) Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms. Urol Sci 21:132–136CrossRef Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P (2010) Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms. Urol Sci 21:132–136CrossRef
20.
Zurück zum Zitat Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E (2006) Histologic features in the urinary bladder wall affected from neurogenic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50:1058–1064PubMedCrossRef Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E (2006) Histologic features in the urinary bladder wall affected from neurogenic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50:1058–1064PubMedCrossRef
21.
Zurück zum Zitat Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245–1253PubMedCrossRef Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245–1253PubMedCrossRef
22.
Zurück zum Zitat Jang J, Park EY, Seo SI, Hwang TK, Kim JC (2006) Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 98:435–439PubMedCrossRef Jang J, Park EY, Seo SI, Hwang TK, Kim JC (2006) Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 98:435–439PubMedCrossRef
23.
Zurück zum Zitat Dmitrieva N, McMahon SB (1996) Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66:87–97PubMedCrossRef Dmitrieva N, McMahon SB (1996) Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66:87–97PubMedCrossRef
24.
Zurück zum Zitat Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818PubMedCrossRef Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818PubMedCrossRef
25.
Zurück zum Zitat Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedCrossRef Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedCrossRef
26.
Zurück zum Zitat Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, Mittleman MA (2008) Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 16:875–880CrossRef Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, Mittleman MA (2008) Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 16:875–880CrossRef
27.
Zurück zum Zitat Hwang JJ, Li HY, Shieh GJ, Chien YF, Hua CH, Lin JW (2008) Illustrating the roles of C-reactive protein in the development of the metabolic syndrome in women—a cross-racial validation. Nutr Metab Cardiovasc Dis 18:671–677PubMedCrossRef Hwang JJ, Li HY, Shieh GJ, Chien YF, Hua CH, Lin JW (2008) Illustrating the roles of C-reactive protein in the development of the metabolic syndrome in women—a cross-racial validation. Nutr Metab Cardiovasc Dis 18:671–677PubMedCrossRef
28.
Zurück zum Zitat Aronson D, Bartha P, Zinder O et al (2004) Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28:674–679PubMedCrossRef Aronson D, Bartha P, Zinder O et al (2004) Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28:674–679PubMedCrossRef
29.
Zurück zum Zitat Khera A, McGuire DK, Murphy SA et al (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46:464–469PubMedCrossRef Khera A, McGuire DK, Murphy SA et al (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46:464–469PubMedCrossRef
30.
Zurück zum Zitat Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462–466PubMedCrossRef Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462–466PubMedCrossRef
Metadaten
Titel
The role of serum C-reactive protein in women with lower urinary tract symptoms
verfasst von
Sheng-Mou Hsiao
Ho-Hsiung Lin
Hann-Chorng Kuo
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 7/2012
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-012-1715-1

Weitere Artikel der Ausgabe 7/2012

International Urogynecology Journal 7/2012 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.